Assessment of bronchodilation induced by beta-adrenergic agent and anti-cholinergic agent in COPD patients, using 3D CT Image analysis - Assessment of bronchodilation induced by beta-adrenergic agent and anti-cholinergic agent in COPD patient

Division of Respiratory Medicine, Hokkaido University Graduate School of Medicine0 个研究点目标入组 30 人开始时间: 2013年10月15日最近更新: 2023年10月17日

试验速览

暂无简介。

•(1) Coexistence of other major pulmonary diseases such as asthma, bronchiectasis, pulmonary fibrosis, tuberculosis, and pulmonary cancer diagnosed by imaging modalities and/or laboratory findings. Asthma is excluded based on clinical history and/or laboratory findings, including levels of IgE and/or eosinophils in blood and/or sputum, but not based on reversibility of airflow limitation. (2) Those who can not adequately inhale beta 2 agonist and/or anti-cholinergic agent. (3) Those who have severe dysfunction in liver or kidney. (4) Those who have unstable cardiovascular disease or potentially fatal arrhythmia. (5) Those who have poor-controlled diabetes or hypertension. (6) Those who have glaucoma. (7) Those who have symptomatic prostate hypertrophy; however, they may be included if they are asymptomatic with pharmaco- therapy or post-surgery of TURP. (8) Those who are considered as inappropriate subjects for any reasons.

发起方

Division of Respiratory Medicine, Hokkaido University Graduate School of Medicine